Company profile
PhaseRx, Inc.
OTC: PZRXQ · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ —GM —SS 27
v0.1 · 5/100 weight · pillars only
↑ balance-sheet leverage, listing tenure · ↓ revenue growth (YoY), market scale
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$20.1M
Employees
10
as of 2026-08-31
Market cap
$1.2k
as of 2026-08-31
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02016
Net income-$20.1M-$20.1M2016
Operating income-$18.3M-$18.3M2016
Total assets$16.4M$16.4M2016
Liabilities$7.2M$7.2M2016
Equity$9.3M$9.3M2016
Revenue trend
FY2014 – FY2016 · USD
FY14
FY15
FY16
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is PhaseRx, Inc.’s revenue?
PhaseRx, Inc. booked $0 in FY2016 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Xcorporeal, Inc.——Speakeasy Cannabis Club Ltd.——Biomagnetics Diagnostics Corp.——Imagin Medical Inc.——CVR Medical Corp.——Lynx Global Digital Finance Corporation——Neighbors
King →Key facts
CEORobert W. Overell
SectorHealthcare
IndustryBiotechnology
HeadquartersSeattle, WA
ExchangeOTC: PZRXQ
Employees10
IPO date2016-05-18
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.